Study of ganagliflozin for kidney disease in people with type 2 diabetes
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a medicine called ganagliflozin can slow down kidney damage in people with type 2 diabetes and chronic kidney disease. If you qualify, you may be able to take part in this study to see if it helps protect your kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have type 2 diabetes and have been diagnosed with chronic kidney disease (a long-term condition where your kidneys slowly lose function).
- Your kidney function and a measure called urine albumin-to-creatinine ratio (UACR) must be within certain ranges (your doctor will check this).
- Your most recent hemoglobin A1c (a blood test that shows your average blood sugar over the past 3 months) must be between 6.5% and 12%.
- If you are already taking an ACE inhibitor or ARB medicine for your kidneys, you must be on a steady dose for at least 4 weeks before starting the study.
- You must not have type 1 diabetes or other kidney diseases not caused by diabetes, and you must not have had conditions like ketoacidosis, a heart attack, or a stroke in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study compares tofogliflozin to metformin to see how well they reduce urine albumin levels (a marker of kidney stress) in people with diabetic kidney disease. You might benefit if your type 2 diabetes is affecting your kidneys despite standard blood-pressure medicines.
This study tests whether a daily medication can slow down kidney damage in people with type 1 diabetes who already have some kidney problems. It may help protect your kidneys from getting worse.
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
This trial tests a new medicine called elecoglipron to see if it helps control blood sugar in people with type 2 diabetes who also have reduced kidney function. You would continue taking your current SGLT2i medication (like dapagliflozin).
Hear when a new T2DM (Type 2 Diabetes Mellitus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.